Renowned medical technology company Masimo (NasdaqGS:MASI) has seen a 6.17% surge in its average one-year price target, now standing at 122.91 / share, up from the previous estimate of 115.77, as of January 16, 2024. This upward revision reflects a positive sentiment from analysts, showcasing confidence in Masimo’s potential.
The price target, an average derived from multiple analyst estimates, ranges from a low of 70.70 to a high of 152.25 / share. While the average represents a 7.03% decrease from the latest closing price of 132.21 / share, the overall outlook remains optimistic for Masimo’s trajectory in the market.
Insights into Fund Sentiment
Masimo captures the interest of 798 funds or institutions, reflecting a slight decrease of 12 owners or 1.48% in the last quarter. The average portfolio weight dedicated to MASI across all funds is 0.21%, showcasing a decline of 7.58%. However, the total shares held by institutions have shown a promising increase in the last three months, climbing by 7.47% to 57,067K shares. The put/call ratio of MASI stands at 0.73, signaling a bullish outlook among investors.
Tracking Shareholder Activity
Politan Capital Management proudly holds 4,714K shares, constituting 8.92% ownership of Masimo. There have been no significant changes in the last quarter in their ownership status.
Capital Research Global Investors own 2,269K shares, representing 4.29% ownership of the company. Their recent filing indicates an increase of 6.02% in shares owned, with a substantial boost of 27.09% in their portfolio allocation in MASI over the last quarter.
Massachusetts Financial Services possesses 1,607K shares, accounting for 3.04% of Masimo’s ownership. Their latest filing reveals a 5.84% increase in shareholding, despite a notable 79.83% reduction in portfolio allocation in MASI over the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares owns 1,578K shares, representing 2.99% of Masimo. Their recent filing indicates a minor 0.07% increase in shares owned, alongside a 44.65% decrease in portfolio allocation in MASI over the last quarter.
Rtw Investments holds 1,462K shares, accounting for 2.77% ownership of Masimo. Their recent filing shows a 2.67% decrease in shares owned and a 3.61% reduction in portfolio allocation within the last quarter.
Delving into Masimo’s Background
(Provided by the company)
Masimo stands as a global medical technology leader, focusing on developing cutting-edge monitoring technologies such as sensors, patient monitors, and connectivity solutions. Known for their Masimo SET®, the company has a rich history of improving patient outcomes and reducing healthcare costs significantly. With a legacy of over 25 years, Masimo continues to innovate, refine, and revolutionize medical monitoring technologies, making a tangible impact on healthcare delivery globally.
Fintel offers a comprehensive investment research platform, catering to individual investors, traders, financial advisors, and small hedge funds. Our data spans the globe, encompassing fundamentals, analyst reports, ownership insights, and much more, providing a holistic view of the market landscape.
Explore the wealth of information Fintel has to offer to elevate your investment decisions and stay ahead in the dynamic world of finance. This story was originally featured on Fintel.
The views and opinions expressed here are solely those of the author and do not represent the opinions of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
